Ylinen, Anni
Hägg-Holmberg, Stefanie
Eriksson, Marika I.
Forsblom, Carol
Harjutsalo, Valma
Putaala, Jukka
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Thorn, Lena M.
,
Funding for this research was provided by:
Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne
Biomedicum Helsinki-säätiö
Samfundet Folkhälsan
Academy of Finland
Wilhelm och Else Stockmanns Stiftelse
Medicinska Understödsföreningen Liv och Hälsa
Novo Nordisk Foundation
Sigrid Juséliuksen Säätiö
Finska Läkaresällskapet
Päivikki ja Sakari Sohlbergin Säätiö
Sydäntutkimussäätiö
EVO governmental grants
Helsingin Yliopisto
Diabetestutkimussäätiö
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 18 January 2021
Accepted: 23 February 2021
First Online: 15 March 2021
Declarations
:
: M.I.E. is a shareholder of BCB Medical Oy. P-H.G. has received lecture honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc, and he is an advisory board member of AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. The other authors declare no disclosures.
: The local ethics committee of each center approved the study protocol, and the study was carried out in accordance with the Declaration of Helsinki.
: Each participant signed a written informed consent.